Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: Workshop perspectives

被引:92
作者
Bell, DA
Longacre, TA
Prat, J
Kohn, EC
Soslow, RA
Ellenson, LH
Malpica, A
Stoler, MH
Kurman, RJ
机构
[1] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Stanford Univ, Ctr Med, Dept Pathol, Div Surg Pathol, Stanford, CA USA
[4] Univ Autonoma Barcelona, Hosp Santa Creu & Sant Pau, Dept Pathol, Barcelona, Spain
[5] Ctr Canc Res, Lab Pathol, NCI, Bethesda, MD USA
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
[7] Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY USA
[8] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX USA
[9] Univ Virginia Hlth Syst, Robert E Fechner Lab Surg Pathol, Charlottesville, VA USA
[10] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD USA
[11] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, Baltimore, MD USA
关键词
serous; ovary; borderline; low malignant potential; atypical proliferative;
D O I
10.1016/j.humpath.2004.03.005
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Although the category of serous borderline ovarian tumor (S-BOT) was established more than 30 years ago, the nomenclature and prognostic significance of various histological features of these neoplasms continues to engender controversy. The Borderline Ovarian Tumor Workshop was held in Bethesda, MD, in August 2003 in an attempt to examine the existing data, establish areas of agreement, and identify areas needing further investigation. This report addresses 6 areas of controversy regarding S-BOT: (1) tumors with and without a micropapillary architecture (typical vs micropapillary type), (2) peritoneal implants, (3) stromal microinvasion, (4) ovarian surface involvement, (5) lymph node involvement, and (6) recurrent tumors. Each of these issues is addressed by summarizing the data in the literature on which the discussions were based, areas of agreement that emerged, divergent opinions and the reasoning behind them, and the conclusions of the participants with recommended nomenclature. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:934 / 948
页数:15
相关论文
共 83 条
  • [1] K-ras mutations in Mullerian inclusion cysts associated with serous borderline tumors of the ovary
    Alvarez, AA
    Moore, WF
    Robboy, SJ
    Bentley, RC
    Gumbs, C
    Futreal, PA
    Berchuck, A
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 80 (02) : 201 - 206
  • [2] [Anonymous], 1971, Acta Obstet Gynecol Scand, V50, P1
  • [3] [Anonymous], 1998, Armed Forces Institute of Pathology
  • [4] AURE JC, 1971, OBSTET GYNECOL, V37, P1
  • [5] BELL DA, 1988, CANCER, V62, P2212, DOI 10.1002/1097-0142(19881115)62:10<2212::AID-CNCR2820621024>3.0.CO
  • [6] 2-W
  • [7] OVARIAN SEROUS BORDERLINE TUMORS WITH STROMAL MICROINVASION - A REPORT OF 21 CASES
    BELL, DA
    SCULLY, RE
    [J]. HUMAN PATHOLOGY, 1990, 21 (04) : 397 - 403
  • [8] Bell DA, 1992, MODERN PATHOL, V5, p61A
  • [9] Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas
    Bell, KA
    Sehdev, AES
    Kurman, RJ
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (04) : 419 - 432
  • [10] BOSTWICK DG, 1986, CANCER, V58, P2052, DOI 10.1002/1097-0142(19861101)58:9<2052::AID-CNCR2820580916>3.0.CO